drugset / Trial / NCT04447768
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
Phase 2
Active not recruiting
100 enrolled
Memorial Sloan Kettering Cancer Center
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in people who have not received a previous treatment for their cancer.
Timeline
- Start
- 2020-12-03
- Primary completion
- 2027-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |